Jade E. Jones, MD

Breast oncologist Jade E. Jones, MD, says she tries to send patients with HR-positive BRCA-mutant TNBC to clinical trials that use PARP inhibitors.

Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.

T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive breast cancer/triple-negative breast cancer in DESTINY-Breast04.